Tianjin Lisheng Pharmaceutical Co.,Ltd.

002393.SZ

002393.SZTianjin Lisheng Pharmaceutical Co.,Ltd. CN flag

Shenzhen

17.02

CNY

+0.26

(+1.55%)

0.70EPS

24.31P/E

4.36BMarket Cap

May 16Next Earn

Upgrade to Unlock Non-US CompaniesTo view real-time data and analysis of companies outside of the United States, upgrade your account to our premium subscription.

Upgrade

ISIN

CNE100000NJ9

Return %

Stock

S&P500

-8.25

12.24

16.26

45.53

-0.64

101.43

Use logarithmic scale

	2012 Y	2013 Y	2014 Y	2015 Y	2016 Y	2017 Y	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y	2024 Y	TTM
Revenue per Share	4.38	4.1	3.03	3.05	3.3	4.03	5.86	6.32	4.73	4.28	4.46	4.46	5.21	5.1
Basic EPS, GAAP	1.16	1.15	0.36	0.45	0.45	0.46	0.72	0.74	0.04	0.48	0.36	1.4	0.72	0.69
Free Cash Flow per Basic Share	0.1	-0.09	-0.86	-0.03	0.14	0.51	0.23	0.7	-0.1	0.42	1.13	0.54	0.13	-0.18
Dividend per Share	0.62	0.64	0.44	0.23	0.3	0.23	0.22	0.22	0.23	0.07	0.21	0.21	0.47	0.44
Book Value per Share	3.09	3.56	3.45	3.66	3.75	3.97	4.4	4.85	4.92	5.02	5.1	6.11	6.7	6.74
Tangible Book Value per Share	10.47	11.04	10.97	11.27	11.32	11.44	17.16	16.65	17.22	16.72	16.4	18.49	17.73	17.42
Basic Weighted Avg Shares	255	255	255	254	257	256	256	256	241	255	257	258	256	263
Sales/Revenue/Turnover	1,117	1,044	774	775	847	1,029	1,504	1,615	1,141	1,092	1,147	1,153	1,336	1,341
Operating Margin (%)	28.81	29.19	11.41	16.58	13.61	9.55	11.43	12.13	5.09	4.18	7.28	11.44	6.75	6.5
Depreciation Expense	25	24	26	25	49	56	55	61	63	60	66	67	81	- -
Net Income, GAAP	297	293	93	114	116	117	185	188	9	122	94	362	185	181
Effective Tax Rate (%)	16.89	15.83	17.12	15.64	13.26	10.71	13.56	13.22	72.15	10.95	20.92	13.89	13.89	14.58
Profit Margin (%)	26.6	28.05	12	14.74	13.65	11.35	12.3	11.65	0.76	11.18	8.16	31.38	13.81	13.47
Working Capital	1,781	1,701	1,308	1,080	993	1,495	1,617	1,749	1,741	1,804	1,895	2,192	2,313	2,359
LT Debt	8	90	70	50	30	10	- -	- -	6	6	5	4	8	8
Total Equity	2,787	2,924	2,910	2,970	3,015	3,080	4,570	4,417	4,302	4,411	4,349	4,903	4,800	4,829
Return on Invested Capital (%)	8.94	8.72	2.4	3.55	3.23	2.79	3.79	3.72	0.37	0.92	1.48	2.42	1.58	1.48
Return on Capital (%)	38.78	31.61	9.29	11.46	11.31	11.11	16.17	15.28	0.71	9.68	7.06	24.43	10.87	9.84
Return on Common Equity (%)	40.51	34.59	10.39	12.63	12.22	11.81	17.25	15.87	0.71	9.89	7.23	25.05	11.2	10.59

Capital Structure

•

in mil. unless spec.

Working Capital

•

in mil. unless spec.

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)	10 years	5 years	1 year
Sales/Revenue/Turnover	7.23%	-2.44%	15.88%
Net Income, GAAP	152.14%	287.22%	-49%
Free Cash Flow	-97.13%	-123.47%	-75.04%
Total Cash Common Dividend	- -	- -	121.11%
Total Equity	5.99%	1.83%	-2.11%

Growth Rates

•

in mil. unless spec.

Quarterly Revenue

•

in mil. unless spec.

Quarterly Earnings Per Share

•

in mil. unless spec.

Quarterly Dividends Per Share

•

in mil. unless spec.

Company Description

CEO: Mr. Fujun Wang
Full Time Employees: 1,604
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Address: No.16, Saida North 1st Road Tianjin People's Republic of China 300385
IPO Date: Apr 23, 2010
Website: lishengpharma.com
Similar Companies: Herbal Dispatch Inc. (LUFFF)
Sequent Scientific Limited (SEQUENT.BO)
Go Life International Limited (GLI.JO)
Huaren Pharmaceutical Co., Ltd. (300110.SZ)
Assertio Holdings, Inc. (ASRT)
Ayurcann Holdings Corp. (AYURF)
Business: Tianjin Lisheng Pharmaceutical Co.,Ltd. engages in the production and sale of chemical medicines. The company offers tablets, hard capsules, dripping pills, freeze-dried powder injections, water injections, and bulk medicines, as well as intermediates, diagnostic reagents, biochemical reagents, and plastic bottles. It also exports its products. The company is based in Tianjin, China. Tianjin Lisheng Pharmaceutical Co.,Ltd. operates as a subsidiary of Tianjin Pharmaceutical Holdings Co., Ltd.

	2012 Y	2013 Y	2014 Y	2015 Y	2016 Y	2017 Y	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y	2024 Y	TTM
Revenue per Share	4.38	4.1	3.03	3.05	3.3	4.03	5.86	6.32	4.73	4.28	4.46	4.46	5.21	5.1
Basic EPS, GAAP	1.16	1.15	0.36	0.45	0.45	0.46	0.72	0.74	0.04	0.48	0.36	1.4	0.72	0.69
Free Cash Flow per Basic Share	0.1	-0.09	-0.86	-0.03	0.14	0.51	0.23	0.7	-0.1	0.42	1.13	0.54	0.13	-0.18
Dividend per Share	0.62	0.64	0.44	0.23	0.3	0.23	0.22	0.22	0.23	0.07	0.21	0.21	0.47	0.44
Book Value per Share	3.09	3.56	3.45	3.66	3.75	3.97	4.4	4.85	4.92	5.02	5.1	6.11	6.7	6.74
Tangible Book Value per Share	10.47	11.04	10.97	11.27	11.32	11.44	17.16	16.65	17.22	16.72	16.4	18.49	17.73	17.42
Basic Weighted Avg Shares	255	255	255	254	257	256	256	256	241	255	257	258	256	263
Sales/Revenue/Turnover	1,117	1,044	774	775	847	1,029	1,504	1,615	1,141	1,092	1,147	1,153	1,336	1,341
Operating Margin (%)	28.81	29.19	11.41	16.58	13.61	9.55	11.43	12.13	5.09	4.18	7.28	11.44	6.75	6.5
Depreciation Expense	25	24	26	25	49	56	55	61	63	60	66	67	81	- -
Net Income, GAAP	297	293	93	114	116	117	185	188	9	122	94	362	185	181
Effective Tax Rate (%)	16.89	15.83	17.12	15.64	13.26	10.71	13.56	13.22	72.15	10.95	20.92	13.89	13.89	14.58
Profit Margin (%)	26.6	28.05	12	14.74	13.65	11.35	12.3	11.65	0.76	11.18	8.16	31.38	13.81	13.47
Working Capital	1,781	1,701	1,308	1,080	993	1,495	1,617	1,749	1,741	1,804	1,895	2,192	2,313	2,359
LT Debt	8	90	70	50	30	10	- -	- -	6	6	5	4	8	8
Total Equity	2,787	2,924	2,910	2,970	3,015	3,080	4,570	4,417	4,302	4,411	4,349	4,903	4,800	4,829
Return on Invested Capital (%)	8.94	8.72	2.4	3.55	3.23	2.79	3.79	3.72	0.37	0.92	1.48	2.42	1.58	1.48
Return on Capital (%)	38.78	31.61	9.29	11.46	11.31	11.11	16.17	15.28	0.71	9.68	7.06	24.43	10.87	9.84
Return on Common Equity (%)	40.51	34.59	10.39	12.63	12.22	11.81	17.25	15.87	0.71	9.89	7.23	25.05	11.2	10.59

	Sep'24	Dec'24	Mar'25
Total Current Assets	2,990	3,060	3,067
Accounts Receivable, Net	257	208	268
Cash, Cash Equivalents & STI	2,270	2,212	2,119
Inventories	227	224	223
Total Current Liabilities	746	747	708
Payables & Accruals	- -	- -	- -
ST Debt	83	43	32
Deferred Revenue	- -	- -	- -

Year	Q1	Q2	Q3	Q4	FY
2023	336	322	254	241	1,153
2024	365	380	279	312	1,336
2025	370	- -	- -	- -	- -

	Sep'24	Dec'24	Mar'25
ST Debt	83	43	32
LT Borrowings	- -	- -	- -
LT Finance Leases	10	8	8
Preferred Equity and Hybrid Capital	- -	- -	- -
Shares Outstanding	258	258	258
Market Capitalization	4,547	4,537	4,390

Year	Q1	Q2	Q3	Q4	FY
2023	0.18	- -	- -	- -	1.4
2024	0.23	- -	- -	- -	0.72
2025	0.21	- -	- -	- -	- -

Tianjin Lisheng Pharmaceutical Co.,Ltd.

Growth Rates

(avg. rate of change)

Company Description

Capital Structure

Working Capital

Growth Rates

(avg. rate of change)

Quarterly Dividends Per Share

Year

Quarterly Revenue

Year

Quarterly Earnings Per Share

Year